Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps

Modular Medical (NASDAQ: MODD) announced that Pivot tubeless insulin patch pump starter kits are now shipping to multiple endocrinology practices for physician training.

Rhea-AI Summary

Modular Medical (NASDAQ: MODD) announced that Pivot tubeless insulin patch pump starter kits are now shipping to multiple endocrinology practices for physician training. After training, pumps will be offered to potential patients within days and weeks.

The system targets adults on multiple daily injections, an estimated 70% of insulin-dependent adults, described as a multi-billion-dollar opportunity. Full commercial launch is planned in phases, starting with select high-volume endocrinology practices and expanding across select metropolitan markets by late 2026.

Positive

• Pivot tubeless insulin patch pump starter kits now shipping to endocrinology practices
• Pumps to be presented to potential patients shortly after physician training
• Targets adults on multiple daily injections, about 70% of insulin-dependent adults
• Phased commercial launch planned, expanding to select metropolitan markets by late 2026
• Company highlights Pivot’s exposure to a multi-billion-dollar diabetes technology opportunity

Negative

• None.

Argus Jun 26 session

+19.90% close to close Open Argus

Details

News Market Reaction – MODD

In the Jun 26 session, MODD gained 19.90%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +19.9% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +19.9% in the session following this news. A strong positive reaction aligns with progress from FDA clearance to initial Pivot deployments, validating the large 70% injection-only population opportunity. Investors may still weigh funding flexibility under the $150,000,000 shelf against future dilution risk.

Key Figures

Injection population: 70% of insulin-dependent adults Launch timing: Late 2026

Injection population

70% of insulin-dependent adults

Adults on multiple daily injections targeted by Pivot pump

Launch timing

Late 2026

Planned expansion of Pivot across select metropolitan markets

Historical Context

5 past events · Latest: Jun 24

5 events

1. Jun 24

   Commercial availability

   24h Move

   -2.2%

   Announced U.S. commercial availability and initial shipments of Pivot pump.

2. Jun 04

   Product website launch

   24h Move

   +6.4%

   Launched PivotPump.com supporting upcoming commercial launch after FDA clearance.

3. Apr 29

   Investor webinar

   24h Move

   -3.3%

   Announced CEO webinar on FDA wins and manufacturing scale-up.

4. Apr 19

   Registered offering

   24h Move

   -7.7%

   Priced registered direct equity offering under existing shelf registration.

5. Apr 16

   Nasdaq compliance

   24h Move

   +3.0%

   Regained compliance with Nasdaq minimum bid price requirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tubeless insulin patch pump, endocrinology, multiple daily injections

3 terms

tubeless insulin patch pump medical

"the Pivot™ tubeless insulin patch pump is now shipping to physician offices"

A tubeless insulin patch pump is a small, wearable device that sticks to the skin like a patch and delivers measured doses of insulin without any tubing. It acts like an automatic medicine dispenser, replacing multiple daily injections and helping keep blood sugar steadier, which matters to investors because it targets a large, growing diabetes market, can drive recurring sales and service revenue, and depends on regulatory approval and insurance coverage for commercial success.

endocrinology medical

"Pivot starter kits are now shipping to multiple endocrinology practices"

Endocrinology is the branch of medicine that studies hormones, which are chemicals produced by glands in the body that regulate important functions like growth, energy, and mood. Understanding how hormones work can reveal insights into health conditions and overall well-being. For investors, it highlights areas of medical research and pharmaceutical development that may influence healthcare trends and market opportunities.

multiple daily injections medical

"adults with diabetes on daily injections who have faced cost, complexity, and usability barriers"

Multiple daily injections (MDI) is a diabetes treatment approach where a person takes several separate insulin shots each day—typically a long-acting dose to cover baseline needs and additional short-acting doses around meals. For investors, MDI signals demand for insulin supplies, injection devices and support services, and can affect adherence and health outcomes; think of it like needing both a monthly subscription and frequent one-off purchases, which shapes recurring revenue and product design opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pivot starter kits are now shipping to multiple endocrinology practices

SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months.

This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin.

The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across select metropolitan markets by late 2026.

For more information on the Pivot system, visit the dedicated site: PivotPump.com and YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product; the Company's commercial deployment plan and its ability to increase the number of practices offering the Pivot product to patients; successful development of Modular Medical's proprietary technologies; whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products; whether Modular Medical can successfully manufacture its products at high volumes; and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.

About Modular Medical

Modular Medical, Inc. (Nasdaq:MODD) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.

Company Contact:

Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com

Investor Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.com

SOURCE: Modular Medical, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Modular Medical (NASDAQ: MODD) announce about Pivot on June 26, 2026?

Modular Medical announced that Pivot tubeless insulin patch pump starter kits are shipping to physician offices for training. According to Modular Medical, after training, these pumps will be offered to potential patients over the following days and weeks as part of a phased commercialization strategy.

When will Modular Medical’s Pivot insulin patch pump be commercially launched?

Pivot’s full commercial launch is planned to roll out in phases. According to Modular Medical, initial focus will be on select high-volume endocrinology practices, with expansion across select metropolitan markets targeted by late 2026 as clinical adoption builds.

Who is the Pivot tubeless insulin patch pump from MODD designed for?

Pivot is designed for adults with diabetes using multiple daily insulin injections. According to Modular Medical, it targets people who have faced cost, complexity, and usability barriers with traditional pump systems, representing an estimated 70% of insulin-dependent adults currently not using pumps.

How is Modular Medical rolling out Pivot starter kits to endocrinology practices?

Pivot starter kits are being shipped to multiple endocrinology practices for physician training. According to Modular Medical, once endocrinology teams complete training, they will begin presenting the Pivot tubeless insulin patch pump to potential patients over the following days and weeks.

What market opportunity does Modular Medical see for the Pivot insulin delivery system?

Modular Medical cites a multi-billion-dollar opportunity for Pivot in diabetes technology. According to Modular Medical, the device focuses on adults on multiple daily injections, estimated at 70% of insulin-dependent adults, who may benefit from a simpler, tubeless insulin patch pump.

Where can patients and clinicians learn more about Modular Medical’s Pivot pump?

Information about the Pivot insulin delivery system is available online. According to Modular Medical, details can be found at the dedicated PivotPump.com website and on the YouTube Pivot Insulin Delivery System channel, searchable using the handle @ModularMedical for educational content.